Table 1.
Patients characteristics | Total population N = 697 | DENV-1 N = 160 | DENV-2 N = 366 | DENV-4 N = 171 |
---|---|---|---|---|
Age, median years (Q1–Q3) | 35 (23–50) | 31 (21–46) | 36 (24–50) | 36 (24–53) |
Sex ratio (M/F) | 0.85 | 0.84 | 0.89 | 0.76 |
Clinical and biological manifestations | ||||
Time of presentation, median days (Q1–Q3) | 3 (2–5) | 4 (3–5) | 4 (2–5) | 2 (1–4) |
Admitted during the critical phase, n (%) | 204 (29.3) | 35 (21.9) | 144 (39.3) | 25 (14.6) |
OR [95% CI] | 1 | 2.3 [1.5–3.6] | 0.6 [0.3–1.1] | |
Gastrointestinal signs, n (%) | 416 (60.6) | 103 (65.2) | 238 (65.8) | 75 (44.9) |
OR [95% CI] | 1 | 1.0 [0.7–1.5] | 0.4 [0.3–0.7] | |
Mucosal bleeding, n (%) | 112 (16.1) | 23 (14.4) | 68 (18.6) | 21(12.3) |
OR [95% CI] | 1 | 1.3 [0.8–2.3] | 0.8 [0.4–1.6] | |
Plasma leakage, n (%) | 100 (14.4) | 16 (10.0) | 73 (20.0) | 11 (6.4) |
OR [95% CI] | 1 | 2.2 [1.3–4.0] | 0.6 [0.3–1.4] | |
Platelet counts, median × 1,000/mL (Q1–Q3) | 118 (64–175) | 116 (86–164) | 104 (38–163) | 150 (110–190) |
Hematocrit, median % (Q1–Q3) | 40 (38–44) | 42 (39–44) | 40 (37–43) | 40 (38–43) |
ASAT, median IU/L (Q1–Q3) | 56 (30–137) | 57 (34–139) | 67 (32–157) | 39 (24–81) |
Immune status | ||||
Secondary infections, n (%) | 387 (55.6) | 75 (46.9) | 224 (61.2) | 88 (51.46) |
OR [95% CI] | 1 | 1.8 [1.2–2.6] | 1.2 [0.8–1.19] | |
Clinical forms | ||||
Uncomplicated dengue, n (%) | 376 (54.0) | 87 (54.4) | 174 (47.6) | 115 (67.3) |
OR [95% CI] | 1 | 0.8 [0.2–1.1] | 1.7 [1.1–2.7] | |
Intermediate severity, n (%) | 169 (24.3) | 48 (30.0) | 92 (25.1) | 29 (17.1) |
OR [95% CI] | 1 | 0.8 [0.5–1.2] | 0.5 [0.3–0.8] | |
Severe dengue, n (%) | 152 (21.8) | 25 (15.6) | 100 (27.3) | 27 (15.8) |
OR [95% CI] | 1 | 2.0 [1.3–3.3] | 1.0 [0.6–1.8] | |
Clinical management | ||||
Hospital stays > 1 day, n (%) | 181 (26) | 34 (21.3) | 112 (30.6) | 35 (20.5) |
OR [95% CI] | 1 | 1.6 [1.1–2.5] | 0.9 [0.6–1.6] |
OR = odds ratio; CI = confidence interval.